Sponsors, others trying new trial methodology

April 2007
Clinical Trials Administrator;Apr2007, Vol. 5 Issue 4, p45
The article provides an outlook for clinical trial methodology. Doctor P. K. Tandon of BioMedical Operations for Genzyme Corp. in Massachusetts asserted that the use of adaptive methodology could benefit a phase II clinical trial. He explained that existing data on a disease could also be used to understand other diseases with the adaptive methodology. He claimed that sponsors and investigators could have deeper knowledge about the disease and drug when they put flexibility in clinical trials.


Related Articles

  • Measuring the Effects of Therapy in Parkinson Disease—Reply. Olanow, C. Warren; Schapira, Anthony H. V. // JAMA: Journal of the American Medical Association;5/26/2004, Vol. 291 Issue 20, p2431 

    Presents a letter to the editor in reply to reader response to the authors' published research on Parkinson disease (PD). Discussion of activities of daily living scores used in the clinical trial; The need for a neuroprotective therapy for PD.

  • Are these data real? Statistical methods for the detection of data fabrication in clinical trials. Al-Marzouki, Sanaa; Evans, Stephen; Marshall, Tom; Roberts, Ian // BMJ: British Medical Journal (International Edition);7/30/2005, Vol. 331 Issue 7511, p267 

    Objectives To test the application of statistical methods to detect data fabrication in a clinical trial. Setting Data from two clinical trials: a trial of a dietary intervention for cardiovascular disease and a trial of a drug intervention for the same problem. Outcome measures Baseline...

  • Treatment of Rotavirus Infection with Nitazoxanide?  // Clinical Infectious Diseases;1/15/2007, Vol. 44 Issue 2, pv 

    The article discusses the clinical trial on the effect of nitazoxanide in treating severe rotavirus diarrhea. The research team has able to exhibit that nitazoxanide's active derivative tizoxanide, inhibited a simian rotavirus with a median effective concentration of 0.5 microgram per...

  • Treatment of chronic obstructive pulmonary disease: Combination or component therapy? Hackam, Daniel G. // CMAJ: Canadian Medical Association Journal;5/13/2003, Vol. 168 Issue 10, p1296 

    Discusses the study 'Combined Salmeterol and Fluticasone in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Randomized Controlled Trial,' by P. Calverley, R. Pauwels et al., published in a 2003 issue of the journal 'The Lancet.' Background on COPD; Overview of the findings;...

  • NXY 059: CPI 22, NXY 059G. Limited, Adis International // Drugs in R&D;2003, Vol. 4 Issue 4, p254 

    NXY 059 [CPI 22, NXY 059G], a nitrone with free radical trapping properties, has potential in the treatment of ischaemic stroke. NXY 059 is based on Centaur Pharmaceuticals' proprietary Nitrone-Related Therapeutics (NRT[sup â„¢]) technology. A generic form of NXY 059, NXY 059G, has been...

  • Mechanism matters.  // Nature Medicine;Apr2010, Vol. 16 Issue 4, p347 

    In this article the author discusses drug's mechanism before it enters clinical trials as the intelligent route to drug discovery. The author offers information on an investigational trial of Alzheimer's disease drug called dimebon and reports significant knowledge related to drug's mechanism...

  • Clinical Trials in Ulcerative Colitis: II. Historical Review. Margolin, Michael L.; Krumholz, Michael P.; Fochios, Steven E.; Korelitz, Burton I. // American Journal of Gastroenterology;Mar1988, Vol. 83 Issue 3, p227 

    Presents a review of the results of clinical trials in ulcerative colitis, as of March 1988. Application of sulfasalazine (SSZ) and its analogs in the treatment of active ulcerative colitis; Effectiveness of combining the oral and topical administration of SSZ; Comparison between the effects of...

  • ENHANCE: Imaging study did not show clinical benefit. Raible, Eric // Cardiology Today;Feb2008, Vol. 11 Issue 2, p19 

    The article provides information on the initial result of the Effect of Combination Ezetimibe and High-Dose Simvastatin versus Simvastatin Alone on Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) clinical trial. Result shows that ezetimibe drug failed to reduce the risk of...

  • Solifenacin economically dominant in OAB.  // PharmacoEconomics & Outcomes News;10/4/2008, Issue 563, p1 

    The article discusses research on solifenacin as a cost-effective option for the treatment of overactive bladder (OAB). It references a study by M. Speakman et al, published in the August 2008 issue of "Current Medical Research and Opinion." The researchers assessed the incremental cost...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics